|
| Friday, 16 October 2020, 09:00 HKT/SGT | |
| |
|
|
|
Names Ms. Yeh-Huang, Chun-Ying as Vice Chairman of the Board Appoints Dr. Liu, Jun as Chief Executive Officer |
HONG KONG, Oct 16, 2020 - (ACN Newswire) - TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company"; stock code: 1875.HK), is pleased to announce that Ms. Yeh-Huang, Chun-Ying, Executive Director, has been appointed as Vice Chairman of the Board while she has resigned as General Manager of the Company. Besides, it has also announced that Dr. Liu, Jun has been appointed as Chief Executive Officer of the Company and will cease to act as Chief Operating Officer and Vice General Manager.
Mr. Fu, Shan, Chairman of the Board of the Company, said, "To implement the strategic development plan of the Company in the next decade, the appointments of the Board and the management will be conducive to optimising the Company's management structure, or initiating a long-term succession plan for the management, so that the Company will achieve long-term sustainable development and be fully equipped to enter the commercialization development stage. Also, this move will enhance the development of the Company's overseas R&D projects and international cooperation projects, promoting its strategic deployment of internationalization."
Ms. Yeh-Huang has established a comprehensive industrial chain platform for the Company, laying major milestones as well as a solid foundation for its long-term development. She will also continue to promote the Company's strategic development, enhancing its brand recognition and public relations.
As a scientist and senior management of the Company, Dr. Liu has been deeply involved in the R&D of biological drugs for years and also possesses profound experience in internationalization management. After taking the helm of CEO, the Board believes that Dr. Liu will continue to pursue the Company's strategic goal of developing TOT BIOPHARM into a leader in the field of China's antibody drug conjugate ("ADC") and establish a competitive CDMO business platform, leading the Company to scale new heights.
Dr. Liu, Jun, aged 53, joined the Company as Deputy General Manager in October 2016, and was appointed as Executive Director, Chief Scientific Officer and Chief Operating Officer in October 2018, March 2019 and April 2020, respectively. He also serves as a member of the Strategic Committee, and is responsible for the Company's R&D, supervising overall operations as well as business development.
Before joining the Company, Dr. Liu was the Senior Scientist of Bayer HealthCare's Global Biologics Development Group in Berkeley, the US, the Chief Researcher of Immunology Department at Beckman Research Institute in California, the US, and also the Executive Director of Biologics Research and Development Department at Shanghai ChemPartner Co., Ltd.
Dr. Liu possesses a professional background with international exposure, holding a PhD in Bioanalytical Chemistry from the University of California, Davis in the US and a Bachelor's degree in Chemistry from the University of Science & Technology of China.
Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
Latest Press Releases
CITIC Telecom CPC Wins Two Awards, Celebrating 'Innovation Never Stops' for 25 Years, recognizing Cybersecurity & Innovation Excellence
Feb 9, 2026 13:28 HKT/SGT
|
|
|
JCB Announces Collaboration with Resorts World Sentosa in Singapore
Monday, February 9, 2026 1:00:00 PM
|
|
|
Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026
Monday, February 9, 2026 10:00:00 AM
|
|
|
playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group
Feb 8, 2026 23:30 HKT/SGT
|
|
|
Mr Liu Xiaojun, on behalf of Fufeng Group, has fully completed the acquisition of Viva World Trade, Inc.
Feb 7, 2026 05:45 HKT/SGT
|
|
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 14:17 HKT/SGT
|
|
|
Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025
Feb 6, 2026 13:13 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|